Innovo Therapeutics
Innovo Therapeutics accelerates discovery of small-molecule drugs for inflammation, immunity, and fibrosis using AI to identify and optimize therapeutic candidates. The company applies its proprietary DeepZema AI platform to analyze biological and chemical data, predict druggability, and prioritize leads for preclinical and clinical development. Innovo operates as a biopharmaceutical R&D and licensing organization and advances programs such as immuno‑metabolic modulator INV-101 (Phase 1 complete). Core technologies include AI‑driven modeling for small‑molecule discovery, and the company collaborates with pharmaceutical partners and research institutions to advance and license assets.
Innovo Therapeutics
Innovo Therapeutics accelerates discovery of small-molecule drugs for inflammation, immunity, and fibrosis using AI to identify and optimize therapeutic candidates. The company applies its proprietary DeepZema AI platform to analyze biological and chemical data, predict druggability, and prioritize leads for preclinical and clinical development. Innovo operates as a biopharmaceutical R&D and licensing organization and advances programs such as immuno‑metabolic modulator INV-101 (Phase 1 complete). Core technologies include AI‑driven modeling for small‑molecule discovery, and the company collaborates with pharmaceutical partners and research institutions to advance and license assets.